FindTrial
Sign In

A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease

A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221135
Enrollment
Unknown
Registered
2010-06-23
Start date
2010-06-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable Coronary Artery Disease

Interventions

investigational material(s) Generic name etc : Ticagrelor INN of investigational material : Ticagrelor Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Admini

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Any Percutaneous Coronary Intervention, more than 3 months prior to randomization or Previous documented acute coronary syndrome (ACS), more than 3 months prior to randomisation - Treatment with ASA

Exclusion criteria

Exclusion criteria: - ACS, transient ischemic attack (TIA), or Stroke within the 3 months prior to randomisation - Known concurrent disease of stroke or TIA with atrial fibrillation - Persons who are being treated with blood clotting agents that cannot be stopped

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026